Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

Annals of Oncology - Tập 25 - Trang 1536-1543 - 2014
H.R. Ali1,2,3, E. Provenzano1,3, S.-J. Dawson1,3,4, F.M. Blows4, B. Liu1,3,4, M. Shah3,4,5, H.M. Earl3,4, C.J. Poole6, L. Hiller6, J.A. Dunn6, S.J. Bowden7, C. Twelves8, J.M.S. Bartlett9,10, S.M.A. Mahmoud11, E. Rakha11, I.O. Ellis11, S. Liu12, D. Gao12, T.O. Nielsen12, P.D.P. Pharoah3,4,5
1Cancer Research UK Cambridge Institute
2Departments of Pathology
3Oncology, University of Cambridge, Cambridge
4Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge
5Strangeways Research Laboratory, Cambridge
6Warwick Clinical Trials Unit, University of Warwick, Coventry
7Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham
8University of Leeds and Leeds Cancer Research UK Centre, St James' Institute of Oncology, Leeds, UK
9Ontario Institute for Cancer Research, Toronto, Canada and Biomarker and Companion Diagnostics, Edinburgh Cancer Research Centre, Edinburgh
10Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
11Department of Pathology and Laboratory Medicine, University of British Columbia; Integrative Oncology Department, British Columbia Cancer Agency, Vancouver
12Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

Tài liệu tham khảo

Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139

Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 203, 10.1056/NEJMoa020177

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Park, 2010, The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity, Cancer Cell, 18, 160, 10.1016/j.ccr.2010.06.014

Liu, 2012, CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer, Breast Cancer Res, 14, R48, 10.1186/bcr3148

Mahmoud, 2011, Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J Clin Oncol, 29, 1949, 10.1200/JCO.2010.30.5037

Baker, 2011, Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade, Histopathology, 58, 1107

Liu, 2011, CD8 cytotoxic T cell and FOXP3 regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes, Breast Cancer Res Treat, 130, 645, 10.1007/s10549-011-1647-3

Shimizu, 1999, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity, J Immunol, 163, 5211, 10.4049/jimmunol.163.10.5211

Mahmoud, 2011, An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer, Breast Cancer Res Treat, 127, 99, 10.1007/s10549-010-0987-8

West, 2013, Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer, Br J Cancer, 108, 155, 10.1038/bjc.2012.524

Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370

Loi, 2013, Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, J Clin Oncol, 31, 860, 10.1200/JCO.2011.41.0902

Ali, 2011, Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance, Breast Cancer Res, 13, R118, 10.1186/bcr3061

Earl, 2012, Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials, Br J Cancer, 107, 1257, 10.1038/bjc.2012.370

Blows, 2010, Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies, PLoS Med, 7, e1000279, 10.1371/journal.pmed.1000279

McShane, 2005, Reporting recommendations for tumor marker prognostic studies (REMARK), J Natl Cancer Inst, 97, 1180, 10.1093/jnci/dji237

Nagalla, 2013, Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis, Genome Biol, 14, R34, 10.1186/gb-2013-14-4-r34

Gruver, 2007, Immunosenescence of ageing, J Pathol, 211, 144, 10.1002/path.2104

Hoppin, 2002, Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies, Ann Epidemiol, 12, 1, 10.1016/S1047-2797(01)00250-2

Janssen, 2010, Missing covariate data in medical research: to impute is better than to ignore, J Clin Epidemiol, 63, 721, 10.1016/j.jclinepi.2009.12.008

Ali, 2011, Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer, Br J Cancer, 104, 693, 10.1038/sj.bjc.6606078

Berke, 1994, The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects, Annu Rev Immunol, 12, 735, 10.1146/annurev.iy.12.040194.003511

Zitvogel, 2011, Immune parameters affecting the efficacy of chemotherapeutic regimens, Nat Rev Clin Oncol, 8, 151, 10.1038/nrclinonc.2010.223

Segal, 2008, Epitope landscape in breast and colorectal cancer, Cancer Res, 68, 889, 10.1158/0008-5472.CAN-07-3095

Bates, 2006, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, J Clin Oncol, 24, 5373, 10.1200/JCO.2006.05.9584

Ignatiadis, 2012, Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis, J Clin Oncol, 30, 1996, 10.1200/JCO.2011.39.5624

Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 25

1536-1543

Thông tin tác giả